The Role of Chemotherapy in Recurrent Ovarian Cancer

Bermejo, M.A. Alonso; Montes, Ana; Lopez, Eva Perez; Viejo, Miguel Ángel Núñez; Gómez, Jesús García; Mata, Jesús García

doi:10.5772/54171

Cited by 1 publication

(1 citation statement)

References 52 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon reviewing previous studies [24,[26][27][28][29], controversies remain regarding the role of maintenance chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. What we learned from previous studies validated the availability of platinum-based doublet chemotherapy regimens, which included platinum plus paclitaxel [18], platinum plus gemcitabine [30], and platinum plus pegylated liposomal doxorubicin [16].…”

Section: Discussionmentioning

confidence: 99%

Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy

Chen,

Hsu,

Hwang

et al. 2024

JCM

View full text Add to dashboard Cite

(1) Background: Our aim was to evaluate the efficacy and adverse effects of maintenance chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer after second-line chemotherapy. (2) Methods: A total of 72 patients from a single institute who had been diagnosed with platinum-sensitive recurrent ovarian cancer and had experienced either complete or partial response after six cycles of second-line chemotherapy were divided into a standard group (n = 31) with six cycles or a maintenance group (n = 41) with more than six cycles. We then compared patient characteristics and survival outcomes between these two groups. (3) Results: In all patients, after primary management for the first recurrence, the maintenance group showed worse survival outcomes. Patients who had not undergone either surgery or radiotherapy were divided into complete response and partial response groups after six cycles of chemotherapy. In patients with partial response, maintenance chemotherapy led to a significant improvement in PFS (median, 3.6 vs. 6.7 months, p = 0.007), but no significant change in in OS. The median cycle number of maintenance chemotherapy was four. (4) Conclusions: Maintenance chemotherapy may still play an important role in patients with platinum-sensitive recurrent ovarian cancer, particularly in selected patient groups.

show abstract